Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,longTermDebt,accountsPayable,capitalSurplus,otherCurrentLiab,retainedEarnings,shortLongTermDebt,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 14, 2021) 4","Short Ratio (Apr 14, 2021) 4","Short % of Float (Apr 14, 2021) 4","Short % of Shares Outstanding (Apr 14, 2021) 4","Shares Short (prior month Mar 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,GNCA,1762000.0,54434800,8751000,,-11983000,,-11983000,3671000,0,-12422000,-12422000,,,,,,0,0,12422000,0,439000,,-11983000,-11983000,82176000.0,1762000.0,83938000.0,1762000.0,56905000.0,4219000.0,66035000.0,5627000.0,13684000.0,66035000.0,9649000.0,5627000.0,,,,,0.0,,,,,,,,,,,60408000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,"Genocea Biosciences, Inc.",-0.2558294,97438288,-2.2948718,55.937496,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,4,1.79,1630526402,0.029999971,1.79,1.8,1.74,162353,NCM,us_market,3.3519588,1630537954,1.85,0.060000062,1.7045438,1.74 - 1.8,1.76,0.0,0.0,11,8,finmb_31231172,NasdaqCM,"Genocea Biosciences, Inc.",USD,190189,208414,0.13999999,0.08484848,1.65 - 4.045,-2.255,-0.55747837,1.65,4.045,1558483200,1619679601,1635337800,1635769800,-0.942,-0.78,-0.63,-2.8412697,0.032,1.9391428,-0.14914286,-0.07691175,2.4053624,-0.6153624,,,,4.045,1.65,1.9391,2.4054,190.19k,208.41k,54.43M,,27.36M,8.86%,61.50%,1.61M,4.33,3.66%,2.96%,1.67M,,,,,,0.00%,"May 21, 2019",,1:8,"May 21, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,"-3,387.49%",-44.56%,-579.95%,1.36M,0.03,,1.36M,-45.39M,-42.84M,-0.9420,,66.03M,1.21,19.64M,1114.87,6.02,0.03,-40.25M,-27.59M,Value,02140,Healthcare,72,"Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.",Cambridge,617 876 8191,MA,1577750400,United States,http://www.genocea.com,86400,100 Acorn Park Drive,617 500 0969,Biotechnology,5th Floor
t-1,GNCA,8982000.0,54434800,7837000,,-14985000,,-14985000,3877000,0,-11714000,-11714000,,-400000.0,,,,0,0,11714000,0,-3271000,,-14985000,-14985000,89511000.0,8982000.0,98493000.0,53000.0,56118000.0,1835000.0,79769000.0,24995000.0,14431000.0,82227000.0,,534000.0,383597000.0,3614000.0,-374668000.0,13862000.0,1672000.0,-1367000.0,-23000.0,3153000.0,-196000.0,3176000.0,-7856000.0,-9642000.0,-329000.0,3596000.0,-1371000.0,57232000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,"Genocea Biosciences, Inc.",-0.2558294,97438288,-2.2948718,55.937496,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,4,1.79,1630526402,0.029999971,1.79,1.8,1.74,162353,NCM,us_market,3.3519588,1630537954,1.85,0.060000062,1.7045438,1.74 - 1.8,1.76,0.0,0.0,11,8,finmb_31231172,NasdaqCM,"Genocea Biosciences, Inc.",USD,190189,208414,0.13999999,0.08484848,1.65 - 4.045,-2.255,-0.55747837,1.65,4.045,1558483200,1619679601,1635337800,1635769800,-0.942,-0.78,-0.63,-2.8412697,0.032,1.9391428,-0.14914286,-0.07691175,2.4053624,-0.6153624,,,,4.045,1.65,1.9391,2.4054,190.19k,208.41k,54.43M,,27.36M,8.86%,61.50%,1.61M,4.33,3.66%,2.96%,1.67M,,,,,,0.00%,"May 21, 2019",,1:8,"May 21, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,"-3,387.49%",-44.56%,-579.95%,1.36M,0.03,,1.36M,-45.39M,-42.84M,-0.9420,,66.03M,1.21,19.64M,1114.87,6.02,0.03,-40.25M,-27.59M,Value,02140,Healthcare,72,"Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.",Cambridge,617 876 8191,MA,1577750400,United States,http://www.genocea.com,86400,100 Acorn Park Drive,617 500 0969,Biotechnology,5th Floor
t-2,GNCA,20205000.0,54434800,7548000,,-4555000,,-4555000,3644000,453000,-10739000,-10739000,,-400000.0,,,,0,453000,11192000,0,6184000,,-4555000,-4555000,85993000.0,20205000.0,106198000.0,52000.0,53237000.0,2112000.0,87625000.0,23815000.0,13758000.0,90328000.0,,567000.0,379836000.0,2886000.0,-359683000.0,13743000.0,0.0,-660000.0,-33000.0,74474000.0,1849000.0,74507000.0,65517000.0,-8297000.0,311000.0,-5902000.0,-664000.0,66513000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,"Genocea Biosciences, Inc.",-0.2558294,97438288,-2.2948718,55.937496,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,4,1.79,1630526402,0.029999971,1.79,1.8,1.74,162353,NCM,us_market,3.3519588,1630537954,1.85,0.060000062,1.7045438,1.74 - 1.8,1.76,0.0,0.0,11,8,finmb_31231172,NasdaqCM,"Genocea Biosciences, Inc.",USD,190189,208414,0.13999999,0.08484848,1.65 - 4.045,-2.255,-0.55747837,1.65,4.045,1558483200,1619679601,1635337800,1635769800,-0.942,-0.78,-0.63,-2.8412697,0.032,1.9391428,-0.14914286,-0.07691175,2.4053624,-0.6153624,,,,4.045,1.65,1.9391,2.4054,190.19k,208.41k,54.43M,,27.36M,8.86%,61.50%,1.61M,4.33,3.66%,2.96%,1.67M,,,,,,0.00%,"May 21, 2019",,1:8,"May 21, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,"-3,387.49%",-44.56%,-579.95%,1.36M,0.03,,1.36M,-45.39M,-42.84M,-0.9420,,66.03M,1.21,19.64M,1114.87,6.02,0.03,-40.25M,-27.59M,Value,02140,Healthcare,72,"Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.",Cambridge,617 876 8191,MA,1577750400,United States,http://www.genocea.com,86400,100 Acorn Park Drive,617 500 0969,Biotechnology,5th Floor
t-3,GNCA,7336000.0,54434800,8587000,,-11321000,,-11321000,3480000,906000,-11161000,-11161000,,-400000.0,,,,0,906000,12067000,0,-160000,,-11321000,-11321000,32479000.0,7336000.0,40516000.0,30000.0,1483000.0,2065000.0,22108000.0,21523000.0,13784000.0,24667000.0,,678000.0,362434000.0,1869000.0,-355128000.0,13627000.0,0.0,-311000.0,-33000.0,5826000.0,734000.0,5859000.0,-4401000.0,-9916000.0,280000.0,391000.0,-317000.0,3144000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,"Genocea Biosciences, Inc.",-0.2558294,97438288,-2.2948718,55.937496,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,4,1.79,1630526402,0.029999971,1.79,1.8,1.74,162353,NCM,us_market,3.3519588,1630537954,1.85,0.060000062,1.7045438,1.74 - 1.8,1.76,0.0,0.0,11,8,finmb_31231172,NasdaqCM,"Genocea Biosciences, Inc.",USD,190189,208414,0.13999999,0.08484848,1.65 - 4.045,-2.255,-0.55747837,1.65,4.045,1558483200,1619679601,1635337800,1635769800,-0.942,-0.78,-0.63,-2.8412697,0.032,1.9391428,-0.14914286,-0.07691175,2.4053624,-0.6153624,,,,4.045,1.65,1.9391,2.4054,190.19k,208.41k,54.43M,,27.36M,8.86%,61.50%,1.61M,4.33,3.66%,2.96%,1.67M,,,,,,0.00%,"May 21, 2019",,1:8,"May 21, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,"-3,387.49%",-44.56%,-579.95%,1.36M,0.03,,1.36M,-45.39M,-42.84M,-0.9420,,66.03M,1.21,19.64M,1114.87,6.02,0.03,-40.25M,-27.59M,Value,02140,Healthcare,72,"Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.",Cambridge,617 876 8191,MA,1577750400,United States,http://www.genocea.com,86400,100 Acorn Park Drive,617 500 0969,Biotechnology,5th Floor
